This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vesnarinone
- DrugBank Accession Number
- DB12082
- Background
Vesnarinone has been used in trials studying the treatment of HIV Infections and Sarcoma, Kaposi.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Vesnarinone (DB12082)
- Weight
- Average: 395.4516
Monoisotopic: 395.184506303 - Chemical Formula
- C22H25N3O4
- Synonyms
- Vesnarinone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Vesnarinone is combined with Cinchocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Aminoquinolines and derivatives / Hydroquinolones / Hydroquinolines / Dimethoxybenzenes / Benzamides / Phenoxy compounds / Anisoles / Benzoyl derivatives / Dialkylarylamines / Alkyl aryl ethers show 9 more
- Substituents
- Alkyl aryl ether / Amine / Amino acid or derivatives / Aminoquinoline / Anisole / Aromatic heteropolycyclic compound / Azacycle / Benzamide / Benzenoid / Benzoic acid or derivatives show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5COW40EV8M
- CAS number
- 81840-15-5
- InChI Key
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
- IUPAC Name
- 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-1,2,3,4-tetrahydroquinolin-2-one
- SMILES
- COC1=C(OC)C=C(C=C1)C(=O)N1CCN(CC1)C1=CC=C2NC(=O)CCC2=C1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0042059
- PubChem Compound
- 5663
- PubChem Substance
- 347828388
- ChemSpider
- 5461
- BindingDB
- 50016980
- ChEBI
- 31237
- ChEMBL
- CHEMBL17423
- ZINC
- ZINC000003781942
- Wikipedia
- Vesnarinone
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Human Immunodeficiency Virus (HIV) Infections / Kaposi's Sarcoma 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 2 Not Available Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0968 mg/mL ALOGPS logP 2.34 ALOGPS logP 2.24 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 15.28 Chemaxon pKa (Strongest Basic) 2.94 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 71.11 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 112.53 m3·mol-1 Chemaxon Polarizability 42.72 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:19 / Updated at February 21, 2021 18:53